Related Experiment Videos

Evaluation of heliox in children hospitalized with acute severe asthma. A randomized crossover trial

E R Carter1, C R Webb, D R Moffitt

  • 1Division of Pediatric Pulmonology, Madigan Army Medical Center, Tacoma, Wash 98410-5000, USA.

Chest
|May 1, 1996
PubMed

Insights

Short-term heliox inhalation did not improve pulmonary function or reduce symptoms in children hospitalized with severe asthma. This study found no significant benefits for breathing heliox compared to air in this pediatric patient group.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Critical Care

Background:

  • Acute severe asthma in children requires effective treatment strategies.
  • Heliox, a helium-oxygen gas mixture, has been explored for its potential to improve airflow in obstructive lung diseases.

Purpose of the Study:

  • To evaluate the efficacy of heliox in improving pulmonary function and clinical outcomes in hospitalized children with acute severe asthma.

Main Methods:

  • A prospective, randomized, double-blind, crossover study was conducted.
  • Children aged 5-18 years with acute severe asthma received heliox and a 30% oxygen-enriched air mixture for 15 minutes each.
  • Pulmonary function tests (FVC, FEV1, PEFR, FEF25-75), clinical scores, and dyspnea scores were assessed.

Main Results:

  • While heliox showed a statistically significant improvement in Peak Expiratory Flow Rate (PEFR) and Mean Mid-expiratory Flow Rate (FEF25-75), it did not significantly improve Forced Vital Capacity (FVC) or Forced Expiratory Volume in 1 second (FEV1).
  • No significant differences were observed in clinical scores or dyspnea scores between heliox and air inhalation.
  • Eleven children completed the study, with no significant differences between baseline and end-study spirometry values.

Conclusions:

  • Short-term inhalation of heliox did not provide significant clinical benefits for children hospitalized with acute, severe asthma.
  • The observed minor improvements in PEFR and FEF25-75 with heliox were not clinically substantial enough to alter overall patient outcomes.
Abstract

Related Concept Videos